CompletedNCT03576976
Official study titleImproving Accessibility and Personalization of Cognitive Remediation for Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including BrooklynSchizophreniaBehavioural studyAges 18–65
- Countries
- United States
- Sponsor
- New York State Psychiatric Institute
CompletedNCT00641745
Official study titleLong-Term Safety, Tolerability, and Effectiveness of Lurasidone in Subjects With Schizophrenia or Schizoaffective Disorder: A Randomized, Active Comparator-Controlled Trial
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–75
- Countries
- United States, Argentina, Brazil, + 5 others
- Sponsor
- Sumitomo Pharma America, Inc.
CompletedNCT05204407
Official study titleLuteolin for the Treatment of People With Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including Los AngelesSchizophreniaPlacebo comparisonAges 18–60
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
CompletedNCT05105542
Official study titleMuscarinic M1 Receptor Availability and Cognition in Schizophrenia
This study has finished and is no longer accepting participants.
In New HavenSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Yale University
CompletedNCT01888107
Official study titleMaintenance of Clinical Response With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Janssen-Cilag S.p.A.
CompletedNCT01431092
Official study titleProlonged-release Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia: a Randomized Clinical Trial
This study has finished and is no longer accepting participants.
In Glostrup MunicipalitySchizophrenia, BipolarityMedication studyAges 18+
- Countries
- Denmark
- Sponsor
- Lone Baandrup